StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Shares of NASDAQ EVOK opened at $0.37 on Tuesday. Evoke Pharma has a 1-year low of $0.36 and a 1-year high of $1.81. The business has a 50-day moving average of $0.53 and a 200-day moving average of $0.73. The company has a debt-to-equity ratio of 1.41, a current ratio of 7.51 and a quick ratio of 7.38. The company has a market capitalization of $12.18 million, a price-to-earnings ratio of -1.42 and a beta of 0.77.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last issued its earnings results on Tuesday, March 8th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter. Evoke Pharma had a negative return on equity of 154.99% and a negative net margin of 529.48%. The company had revenue of $0.36 million during the quarter.
About Evoke Pharma (Get Rating)
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.